Rockefeller Capital Management L.P. Sells 8,624 Shares of CVS Health Corporation $CVS

Rockefeller Capital Management L.P. lessened its stake in CVS Health Corporation (NYSE:CVS) by 2.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 300,770 shares of the pharmacy operator’s stock after selling 8,624 shares during the period. Rockefeller Capital Management L.P.’s holdings in CVS Health were worth $23,869,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of CVS. Kingsview Wealth Management LLC boosted its stake in shares of CVS Health by 316.2% in the 3rd quarter. Kingsview Wealth Management LLC now owns 104,432 shares of the pharmacy operator’s stock valued at $7,873,000 after purchasing an additional 79,340 shares in the last quarter. Intech Investment Management LLC grew its stake in shares of CVS Health by 50.3% during the third quarter. Intech Investment Management LLC now owns 86,564 shares of the pharmacy operator’s stock valued at $6,526,000 after purchasing an additional 28,953 shares during the last quarter. Hamlin Capital Management LLC acquired a new stake in shares of CVS Health in the 4th quarter valued at $160,844,000. Cresset Asset Management LLC increased its position in CVS Health by 56.8% in the third quarter. Cresset Asset Management LLC now owns 35,481 shares of the pharmacy operator’s stock worth $2,675,000 after purchasing an additional 12,849 shares during the period. Finally, Capitolis Liquid Global Markets LLC acquired a new stake in shares of CVS Health during the 3rd quarter worth approximately $11,308,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

Insider Activity at CVS Health

In other news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares in the company, valued at approximately $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Larry Robbins sold 370,462 shares of CVS Health stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the transaction, the director directly owned 4,824,799 shares in the company, valued at $450,877,466.55. The trade was a 7.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is owned by corporate insiders.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS announced a broad expansion of GLP-1 support across more than 9,000 CVS Pharmacy locations and MinuteClinic, including pharmacist guidance, lower-cost options for eligible Medicare patients, side-effect management products, and new virtual care visits. The move could strengthen CVS’s role in a fast-growing weight-loss drug market and drive more pharmacy and clinic traffic. Article: CVS Pharmacy® expands GLP?1 support to lower costs, improve access, and help patients stay on therapy
• Positive Sentiment: Unusual options activity showed heavy call buying, suggesting traders are positioning for further upside in CVS shares. Article: A Look at CVS Health Corp (CVS) After 3.0% Gain — GF Value $77.69 vs Price $101.30
• Positive Sentiment: CVS was also highlighted in multiple articles as a momentum stock and was upgraded to Buy by Wall Street Zen, which may be reinforcing investor optimism. Article: Why CVS Health (CVS) is a Top Momentum Stock for the Long-Term
• Neutral Sentiment: CVS also published a separate newsroom item about soccer-related community events, which is likely a low-impact brand/marketing update rather than a financial driver. Article: CVS Continues To Celebrate Soccer With Community Events

Analyst Ratings Changes

Several equities analysts have recently issued reports on CVS shares. Morgan Stanley boosted their target price on CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a research report on Thursday, June 4th. Argus increased their target price on CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a report on Thursday, May 14th. Barclays lifted their price objective on shares of CVS Health from $101.00 to $106.00 and gave the company an “overweight” rating in a report on Tuesday, May 26th. Leerink Partners reaffirmed an “outperform” rating and issued a $98.00 target price on shares of CVS Health in a research report on Thursday, March 5th. Finally, Wells Fargo & Company boosted their target price on shares of CVS Health from $102.00 to $103.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Twenty-two investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $100.68.

CVS Health Price Performance

CVS Health stock opened at $101.62 on Tuesday. The firm has a market cap of $129.66 billion, a PE ratio of 44.77, a price-to-earnings-growth ratio of 0.96 and a beta of 0.62. The stock’s fifty day moving average price is $89.76 and its two-hundred day moving average price is $81.67. CVS Health Corporation has a one year low of $58.50 and a one year high of $103.12. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, research analysts expect that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.